GlassScriptPhysician profile
Ezmin George
NPI 1760635650
$824.50
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $94.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $199.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $167.11 | 2019 | |
| Philips North America LLC | $138.23 | 2019-2020 | |
| Genentech USA, INC. | $129.32 | 2019 | |
| Glaxosmithkline, LLC. | $43.89 | 2019 | |
| Masimo Corporation | $42.81 | 2020 | |
| Grifols USA, LLC | $36.98 | 2019 | |
| Advanced Respiratory, INC | $35.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.54 | 2019 | |
| Mylan Specialty L.P. | $14.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ezmin George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.